title: Molecular physiology, biochemistry, and pharmacology of Alzheimer's amyloid precursor protein (APP).
abstract: The function of APP is not yet known in detail but growing evidence exists that APP may mediate cell interactions with the cell surface or soluble glycoproteins and defense mechanisms in the CNS involving the immune system. We describe here the finding that almost all CD4+ lymphocytes and the majority of CD8+ lymphocytes were positive for A beta and the antibodies against A beta or APP did not inhibit the [3H]-thymidine uptake of mitogen-treated lymphocytes significantly. There were no differences in the A beta immunoreactivity on the cell surface of lymphocytes between Alzheimer's disease (AD) and control samples. Excessive amyloidogenic pathway of APP processing may be the final common pathway involved in the pathogenesis of AD. Thus, the identification of proteases or factors leading to aberrant proteolysis which process APP to yield a variety of potentially amyloidogenic fragments would promise pharmacological targets to develop anti-AD drugs. In attempts to define the proteases or factors which alter the balance between nonamyloidogenic and amyloidogenic processing pathways, our study indicates that thrombin or acetylcholinesterase(AChE)-associated protease may be involved in the amyloidogenic processing pathway of APP in vivo to generate amyloidogenic intermediates linked to amyloid deposition. Highly specific and dose-dependent direct modulation of APP processing by biologically available metal ions including Ca2+, Zn2+, Fe2+/Fe3+ and Al3+ suggest the disrupted metal homeostasis as factors leading to overaccumulation of APP and subsequent aberrant proteolysis utilizing excessive amyloidogenic processing pathway. There is mounting evidence that at least some of the neurotoxicity associated with AD is due to fragments from APP. Most research has focused on the toxic effect and the ion channel activity of A beta in causation of the disease. The possible role of other cleaved products of APP is less clear. We investigated the channel-forming ability of various products of APP when applied to Xenopus oocytes and their neurotoxicity in vitro. CT105 peptide was found to be exceedingly potent at 500 nM concentration in forming nonselective ion channels during application from either outside or inside the oocyte and more toxic than either of the A beta fragments, A beta 25-35, or A beta 1-40. Taken together, these results suggest the possible involvement of CT peptide in inducing the neurotoxicity characteristic of AD through the direct damage on the cell membrane. Therefore, we hypothesize that amyloidogenic CT may make nonselective ion channels or pores in the membrane and may cause neuronal death in the early stage of AD and then further metabolized to more stable and less toxic A beta which may be finally deposited in the brain where it could inflict further toxicity to neurons. Here we report successful inhibition of APP gene expression by antisense oligodeoxynucleotides at the mRNA or the protein level in in vitro and cell culture systems.
authors.affiliation: Department of Pharmacology, College of Medicine, Seoul National University, Korea.
authors.forename: Y H
authors.initials: YH
authors.lastname: Suh
authors.forename: Y H
authors.initials: YH
authors.lastname: Chong
authors.forename: S H
authors.initials: SH
authors.lastname: Kim
authors.forename: W
authors.initials: W
authors.lastname: Choi
authors.forename: K
authors.initials: K
authors.lastname: Min
authors.forename: S J
authors.initials: SJ
authors.lastname: Jeong
authors.forename: S P
authors.initials: SP
authors.lastname: Fraser
authors.forename: M B
authors.initials: MB
authors.lastname: Djamgoz
mesh_terms: D000544:Alzheimer Disease / Q000209:etiology* / Q000378:metabolism*; D016564:Amyloid beta-Protein Precursor / Q000378:metabolism*; D015870:Gene Expression / Q000235:genetics*; D006801:Humans; D008214:Lymphocytes / Q000378:metabolism; D008967:Molecular Biology; D010455:Peptides / Q000494:pharmacology
chemical_list: D016564:Amyloid beta-Protein Precursor; D010455:Peptides